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Although sleep apnea-hypopnea syndrome (SAHS) is highly prevalent in patients with type
2 diabetes (T2D), it is unknown whether or not subjects with and without T2D share the
same sleep breathing pattern.
Methodology/Principal findings
A cross-sectional study in patients with SAHS according to the presence (n = 132) or not
(n = 264) of T2D. Both groups were matched by age, gender, BMI, and waist and neck cir-
cumferences. A subgroup of 125 subjects was also matched by AHI. The exclusion criteria
included chronic respiratory disease, alcohol abuse, use of sedatives, and heart failure. A
higher apnea hypopnea index (AHI) was observed in T2D patients [32.2 (10.2–114.0) vs.
25.6 (10.2–123.4) events/hours; p = 0.002). When sleep events were evaluated separately,
patients with T2D showed a significant increase in apnea events [8.4 (0.1–87.7) vs. 6.3
(0.0–105.6) e/h; p = 0.044), as well as a two-fold increase in the percentage of time spent
with oxygen saturation <90% [15.7 (0.0–97.0) vs. 7.9 (0.0–95.6) %; <0.001)], higher rates
of oxygen desaturation events, and also higher daily sleepiness [7.0 (0.0–21.0) vs. 5.0
(0.0–21.0); p = 0.006)] than subjects without T2D. Significant positive correlations be-
tween fasting plasma glucose and AHI, the apnea events, and CT90 were observed. Fi-
nally, multiple linear regression analyses showed that T2D was independently associated
with AHI (R2 = 0.217), the apnea index (R2 = 0.194), CT90 (R2 = 0.222), and desaturation
events.
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Conclusions/significance
T2D patients present a different pattern of sleep breathing than subject without diabetes.
The most important differences are the severity of hypoxemia and the number of apneas
whereas the incidence of hypopnea episodes is similar.
INTRODUCTION
Sleep apnea-hypopnea syndrome (SAHS) is well established as an independent risk factor for
hypertension, myocardial infarction, and stroke [1]. In addition, the available data suggest that
a long-term exposure to intermittent hypoxia and sleep fragmentation also contribute to disor-
ders of glucose metabolism [2]. In this regard, a high prevalence of fasting hyperglycemia, insu-
lin resistance, and type 2 diabetes mellitus (T2D) has been found among SAHS patients in
comparison with healthy subjects [3, 4].
Alternatively, because of its considerable vascularization and abundant collagen and elastin
fibers, the lung parenchyma suffers the harmful effects of T2D, and both insulin resistance and
chronic hyperglycemia have been proposed as contributors to the development of SAHS [5].
An analysis of the Sleep Heart Health Study found that patients with T2D had increased sleep-
disordered breathing and more severe sleep hypoxemia, although after correcting for the main
factors involved in the development of SAHS this difference in sleep hypoxemia was eliminated
[6]. Additionally, in non-obese rats, Ramadan et al. [7] demonstrated that insulin resistance
was one of the primary mechanisms leading to sleep apnea, and that treatment with metfor-
min, a drug currently used to increase insulin sensitivity, reversed and prevented these epi-
sodes. Recently, we have contributed to demonstrating that T2D is an independent risk factor
for severe nocturnal hypoxemia and the impairment of lung function parameters [8, 9]. These
data are significant because the impairment of respiratory capacity and nocturnal hypoxia are
well-recognized cardiovascular risk factors which can be added to the classic cardiovascular
risk factors associated with T2DM [10, 11].
However, it is unknown whether or not patients with T2D share the same sleep breathing
pattern as subjects without diabetes. On this basis, the aim of this cross-sectional study was to
compare the characteristics of polysomnography records in patients with SAHS according to
the presence of T2D. Both groups were closely matched by the most important variables that
could affect the prevalence and severity of sleep-disordered breathing.
MATERIALS ANDMETHODS
Ethic statement
Informed written consent was obtained from all participants, and the human ethics committee
from the Hospital Universitari Vall d’Hebrón approved the study.
Description of patients
This was a retrospective study investigating the effect of T2D on the sleep breathing pattern. A
total of 732 patients with T2D evaluated for suspected SAHS at the Sleep Unit of our university
hospital between January 2012 and August 2013 were screened. Inclusion criteria included: age
older than 18 years, Caucasian origin, known type 2 diabetes for longer than 5 years, non-active
tobacco smoking, an apnea hypopnea index (AHI) higher than 10 events/hour, and polysom-
nographic studies with more than 5 hours of correct signal recording.
Sleep Breathing Pattern in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0119073 March 11, 2015 2 / 9
Among the 244 patients who met these criteria, 113 were excluded. Reasons for exclusion
were the following: chronic pulmonary disease (n = 39), narcolepsy (n = 4), stroke (n = 15),
malignancy (n = 11), heart failure (n = 16), abuse of alcohol (> 40 g/day for men and> 20 g/
day for women) or use of sedatives (n = 8), goitre with obstructive or compressive symptoms
(n = 6), hemoglobin lower that 11g/dL (n = 3), treatment with steroids (n = 14), chronic renal
failure (n = 6), and clinical manifestations of diabetic autonomic neuropathy (ie. orthostatic
hypotension, gastroparesis diabeticorum, fecal incontinence, neurogenic bladder, anhidrosis or
severe erectile dysfunction) (n = 1). No pregnant women were evaluated. A complete physical
examination was performed (with special attention to neurological, cardiopulmonary, and ear,
nose and throat evaluations), and a chest radiography was performed on all patients included
in the study.
We aimed to select two controls for every patient with T2D and, consequently, 262 subjects
without diabetes evaluated at the same Sleep Unit served as a control group. Both groups were
closely matched by age, gender, body mass index (BMI), and waist and neck circumferences.
Similarly to patients with diabetes, only polysomnographic studies with more than 5 hours of
correct signal recording were included in the control group.
Treatment for T2D was heterogeneous, and included combined treatment with metformin
plus basal insulin (17.5%), basal plus or basal bolus therapy (13.7%), metformin plus sulphony-
lureas (29.0%), metformine alone (11.4%), and diet (4.5%). The remaining thirty-one patients
(23.6%) were under different oral treatment combinations including thiazolidinediones, dipep-
tidyl peptidase-4 inhibitors, and human glucagon like peptide-1 analogues. The main clinical
characteristics and metabolic data of the study population are shown in Table 1. However, pre-
vious groups were not equally by the AHI, a known potential confounding factor when metrics
of SAHS are evaluated. Therefore, 125 from the 132 patients with T2D were also matched (1:1)
to 125 controls not only by the previous conditions but also by the AHI.
Measurement of sleep disorders of breathing
Overnight sleep study was conducted in a private room at the Sleep Unit using a computerized
polysomnography device (Compumedics E Series, Abbotsdorf, Australia). Polysomnography
included recordings of six electroencephalographic channels, bilateral electro-oculograms, chin
and tibial electromyogram, electrocardiogram, airflow by nasal pressure transducer and orona-
sal thermocouples, as well as oxygen saturation by finger pulse oximeter. An expert scorer
blinded to the study reviewed all sleep studies manually. An apnea was defined as the cessation
Table 1. Main clinical characteristics and metabolic data of participants included in the study according to the presence of type 2 diabetes.
T2D Non T2D Mean difference (95% CI) p value
n 131 262 - -
Age (yrs) 53.3 ± 11.2 52.3 ± 10.6 1.2 (−1.0 to 3.5) 0.279
Women (%) 62.6 62.6 - -
BMI (Kg/m2) 41.3 ± 8.8 42.0 ± 8.5 −0.7 (−2.5 to 1.1) 0.450
Neck circumference (cm) 41.7 ± 3.0 41.2 ± 3.6 0.4 (−0.7 to 1.6) 0.445
Waist circumference (cm) 123.5 ± 16.9 120.9 ± 16.7 2.6 (−1.9 to 7.1) 0.258
Fasting glucose (mg/dl) 167.0 ± 53.4 98.6 ± 11.1 68.3 (3.6 to 61.2) <0.001
HbA1c (%) 7.8 ± 1.6 5.7 ± 0.3 2.1 (0.1 to 1.8) <0.001
HbA1c (mmol/mol) 62.0 ± 17.5 39.0 ± 3.3 23.0 (1.1 to 19.7) <0.001
BMI: body mass index; HbA1c: glycated hemoglobin
doi:10.1371/journal.pone.0119073.t001
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of airflow with duration of at least 10 seconds. Differentiation was made between obstructive
and central apneas according to the respiratory effort channels (presence or absence of thora-
coabdominal movements). Hypopnea was defined as a>30% reduction in nasal cannula trac-
ing with a duration of at least 10 seconds associated with a cyclical dip in arterial oxygen
saturation (SaO2) 3%. The AHI was defined as the sum of apneas plus hypopneas divided by
the total hours of sleep. On this basis, SAHS was defined as an AHI 10 events/hour, and pa-
tients were divided into non-SAHS (AHI< 10 events/hour), mild SAHS (AHI between 10 and
20 events/hour), moderate SAHS (AHI between 21 and 29 events/hour), and severe SAHS
(AHI>30 events/hour). Similarly, the apnea index (AI) and the hypopnea index (HI) were de-
fined as the number of apnea or hypopnea events divided by the total hours of sleep. Three ox-
ygen saturation measures were assessed: the cumulative percentage of time spent with oxygen
saturations below 90% (CT90), and the basal and the average SaO2. In addition, the oxygen
desaturation index (ODI) per hour was calculated by dividing the total number of oxygen desa-
turation events by the total hours of sleep. Four different oxygen desaturation thresholds (re-
ductions in SaO2 equal or greater than 2%, 3%, 4%, and 5%) as indicators of hypoxemia
severity (ODI-2%, ODI-3%, ODI-4%, and ODI-5%) were also determined.
The degree of sleepiness was assessed using the Epworth Sleepiness Scale (ESS), a widely
used questionnaire based on the tendency to fall asleep during various daytime situations [12].
A score of 10 or more is considered sleepy.
T2D was defined according to the criteria recommended by the Expert Committee on the
Diagnosis and Classification of Diabetes [13]. Sixty-three of the 131 patients with T2D were
under metformin treatment alone, whereas fifteen patients were under diet counseling alone.
The remaining subjects were under mixed therapies including other oral and subcutaneous
antidiabetic agents.
Fasting plasma glucose [hexoquinase method (Olympus Diagnostica GmbH, Hamburg,
Germany)] was obtained from all subjects with and without T2D. HbA1c (chromatography)
was obtained from all patients with T2D and 82.0% (n = 215) of subjects without diabetes.
Statistical analysis
The normal distribution of the variables was evaluated using the Kolmogorov-Smirnov test.
Data were expressed either as the mean ± SD, percentage or median (total range). For paramet-
ric tests, AHI, AI, HI, and CT90 were logarithmically transformed to achieve a normal distribu-
tion. Comparisons between groups were performed using the Student’s t test or the Mann-
Whitney U test for continuous variables, as well as the χ2 test for categorical variables.
The relationship between the continuous variables was examined by the Pearson linear cor-
relation test. Several stepwise multiple linear regression analyses to explore the variables inde-
pendently related to measurements of sleep breathing (AHI, AI, HI, CT90, average and
minimum SaO2, ODI-2%, ODI-3%, ODI-4%, and ODI-5%) were performed in the whole pop-
ulation. The independent variables included in the analyses were: gender, age, BMI, basal SaO2,
neck circumference, waist circumference, somnolence score, and the presence or absence of
T2D. All “p” values were based on a two-sided test of statistical significance. Significance was
accepted at the level of p<0.05. Statistical analyses were performed using the SSPS statistical
package (SPSS, Chicago, IL, USA).
RESULTS
The polysomnographic parameters of the study population are presented in Table 2. Patients
with T2D showed a higher AHI than subjects without diabetes [32.2 (10.2–114.0) vs. 25.6
(10.2–123.4) events/hour; p = 0.002]. In addition, a higher prevalence of severe SAHS was
Sleep Breathing Pattern in Type 2 Diabetes
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observed in patients with T2D (54.2% vs. 41.9%; p = 0.008). When sleep events were evaluated
separately, a similar frequency of hypopnea events was present in patients with and without di-
abetes [16.5 (0.0–75.3) vs. 15.1 (0.0–71.4) e/h; p = 0.285]. However, patients with T2D showed
a higher number of apnea events [8.4 (0.1–87.7) vs. 6.3 (0.0–105.6) e/h; p = 0.044]. No differ-
ences in the number of either central or obstructive apnea events were observed in our study.
Patients with T2D spent a two-fold higher percentage of time with oxygen saturation below
90% in comparison with subjects without diabetes [15.7 (0.0–97.0) vs. 7.9 (0.0–95.6) %;
p<0.001). Similarly, the average SaO2 was lower in patients with T2D [92.0 (75.0–98.0) vs. 93.0
(81.0–100.0) %; p = 0.026], as well as the minimum SaO2 [71.0 (37.0–98.0) vs. 75.0 (37.5–
97.0)%; p = 0.033], and higher rates of ODI events were observed in patients with T2D. Regard-
ing somnolence, patients with T2D showed higher daily sleepiness [7.0 (0.0–21.0) vs. 5.0 (0.0–
21.0); p = 0.006] than subjects without diabetes.
When the prevalence of apnea and hypopnea events was separately evaluated in the sub-
group of patients also matched by the AHI, patients with T2D still presented a significantly
higher number of apnea episodes [7.4 (0.1–85.7) vs. 5.0 (0.0–105.6); p = 0.036] in comparison
subjects without diabetes (Table 3). However, between both subgroups, no differences in oxy-
gen measurements were observed (Table 4).
Univariate analysis showed that fasting plasma glucose was positively correlated with AHI
(log) (r = 0.147, p = 0.005), the apnea index (log) (r = 0.111, p = 0.039), and CT90 (log) (r =
0.150, p = 0.006). However, no significant correlation was observed between those parameters
and HbA1c.
Finally, multiple linear regression analyses showed that the presence of T2D was inde-
pendently associated with AHI (beta = −0.003, p = 0.013, R2 = 0.217), the apnea index
(beta = −0.240, p = 0.009, R2 = 0.194), CT90 (beta = −0.279, p = 0.002, R2 = 0.222), ODI 2%
(beta = −0.280, p = 0.005, R2 = 0.178), ODI 3% (beta = −0.239, p = 0.010, R2 = 0.175), ODI
4% (beta = −0.249, p = 0.008, R2 = 0.164), and ODI 5% (beta = −0.246, p = 0.009, R2 = 0.169)
(Table 4).
Table 2. Pulmonary parameters of participants included in the study according to the presence of
type 2 diabetes.
T2D Non T2D p value
n 131 262 -
AHI (events/hour) 32.2 (10.2–114) 25.6 (10.2–123.4) 0.002
Apnea index (events/hour) 8.4 (0.1–87.7) 6.3 (0.0–105.6) 0.044
Hypopnea index (events/hour) 16.5 (0.0–75.3) 15.1 (0.0–71.4) 0.285
Basal SaO2 (%) 96.0 (86.0–100.0) 95.0 (56.0–100.0) 0.646
Average SaO2 (%) 92.0 (75.0–98.0) 93.0 (81.0–100.0) 0.026
Minimum SaO2 (%) 71.0 (37–98) 75.0 (37.5–97.0) 0.033
CT90 (%) 15.7 (0.0–97.0) 7.9 (0.0–95.6) 0.006
ODI 2% (events/hour) 42.2 (8.0–284.0) 33.0 (0.0–129.1) 0.014
ODI 3% (events/hour) 35.4 (7.0–278) 26.0 (0.0–123.0) 0.037
ODI 4% (events/hour) 28.6 (1.9–221.0) 18.4 (0.0–121.0) 0.014
ODI 5% (events/hour) 21.9 (0.8–186.0) 12.5 (0.0–115.0) 0.010
EES 7.0 (0–21.0) 5.0 (0–21.0) <0.001
AHI: apnea-hypopnea index; SaO2: oxygen arterial saturation; CT90: cumulative percentage of time spent
with oxygen saturation below 90%; ODI: oxygen desaturation index; EES: Epworth Sleepiness Scale score.
doi:10.1371/journal.pone.0119073.t002
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DISCUSSION
In the present study we provide evidence that T2D presents a characteristic pattern of breath-
ing during sleep, with increased apnea events but with no differences in hypopnea episodes. In
addition, our results showing an impairment of nocturnal oxygen saturation and daily sleepi-
ness in T2D, reinforce and extend previous reports [9, 14]. Overall, our results suggest that pa-
tients with T2D have a more severe sleep breathing disorders than subjects without diabetes.
This is is an important finding because sleep related hypoxia is a major stimulus leading to oxi-
dative stress and endothelial dysfunction [15, 16], and may contribute to the increased risk of
fatal and non-fatal cardiovascular events observed in T2D. Finally, at the same level of AHI, pa-
tients with T2D still present a higher number of apnea events, with a consequent decrease in
hypopnea events, but without changes in oxygen saturation measures.
The mechanisms by which T2D patients with SAHS present more severe episodes of airflow
reduction during sleep breathing continue to be not fully understood. It has been suggested
that there is an interaction between pulmonary function, adipose tissue, and systemic inflam-
mation. Therefore, the increased levels of cytokines (i.e., IL-6 and TNF-alpha) that activate nu-
clear factor kappa B and the releasing of free fatty acids by excess adipose tissue might be
involved in the pathogenic mechanisms leading to apnea in humans [17, 18]. Data supporting
this hypothesis include how circulating levels of soluble TNF-alpha soluble receptor (sTNF-R)
type 1, but not sTNF-R type 2, were related to reduced lung volumes and airflow limitation in
morbidly obese patients prior to the development of a clinically recognized respiratory disease
[18]. Similarly, the administration of etanercept, a TNF-alpha antagonist, achieved a significant
reduction of sleepiness and sleep apnea and hypopnea events in obese patients with severe
SAHS [19].
Table 3. Main clinical characteristics, metabolic data, and pulmonary parameters when patients with T2D and subjects without diabetes are
matched not only by age, gender, BMI, and neck and waist circumferences, but also by AHI.
T2D (n = 125) Non T2D (n = 125) Mean difference (95% CI) p value
Age (yrs) 53.7±11.1 51.5±9.2 2.2 (−0.3 to 4.7) 0.091
Women (%) 60.8 60.8 - -
BMI (Kg/m2) 40.8±8.6 42.0±7.4 −1.1 (−3.1 to 0.8) 0.266
Neck circumference (cm) 41.5±2.8 41.8±3.5 −0.3 (−1.6 to 0.9) 0.622
Waist circumference (cm) 122.6±16.9 122.8±14.2 −0.1 (−5.0 to 4.7) 0.952
Fasting glucose (mg/dl) 166.2±52.4 98.5±11.0 67.6 (57.6 to 77.6) <0.001
HbA1c (%) 7.8±1.6 5.7±0.3 2.1 (1.7 to 2.4) <0.001
AHI (events/hour) 31.3 (10.2–106.3) 31.1 (10.3–106.3) - 0.934
Apnea index (events/hour) 7.4 (0.1–85.7) 5.0 (0.0–105.6) - 0.036
Hypopnea index (events/hour) 16.1 (0.0–75.3) 20.2 (0–71.4) - 0.005
Basal SaO2 (%) 96.0 (86.0–100.0) 95.0 (56.0–100.0) - 0.154
Average SaO2 (%) 93.0 (75.0–98.0) 93.0 (81.0–97.0) - 0.820
Minimum SaO2 (%) 72.0 (37.0–98.0) 75.0 (37.0–97.0) - 0.070
CT90 (%) 14.2 (0.1–97.0) 10.9 (0.1–95.0) - 0.188
ODI 2% (events/hour) 41.5 (8.0–172.6) 42.0 (9.9–105.6) - 0.949
ODI 3% (events/hour) 31.6 (7.0–278.0) 33.5 (0.0–98.0) - 0.913
ODI 4% (events/hour) 25.5 (1.9–206.3) 24.8 (0.0–98.0) - 0.828
ODI 5% (events/hour) 18.8 (0.8–106.0) 17.2 (0.0–97.0) - 0.659
AHI: apnea-hypopnea index; BMI: body mass index; HbA1c: glycated hemoglobin
doi:10.1371/journal.pone.0119073.t003
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Metabolic pathways related to insulin resistance have also been advocated as being crucial
in initiating lung abnormalities in subjects without diabetes [20]. In this regard, Ramadan et al
[17] demonstrated that insulin resistance was one of the primary mechanisms leading to sleep
apnea in rats, and that treatment with metformin, an insulin-sensitizing drug, not only pre-
vented but also reversed apneic episodes.
The deleterious effect of diabetes on the central respiratory system has also been described
[21]. An impairment of ventilatory drive associated with leptin resistance has been shown in
obese patients [22]. These clinical observations are supported by experimental studies per-
formed in streptozotocin-induced diabetic rats showing a significant reduction in the ventilato-
ry response to hypercapnic and hypoxic challenges which was prevented with insulin
treatment [23]. Resnick et al [6], using cross-sectional data from the Sleep Heart Health Study,
after adjustment for BMI and other potential confounders, found that patients with diabetes
had more episodes of periodic breathing, an abnormality of the central control of ventilation,
Table 4. Stepwise multiple linear regression analysis of variables associated with parameters obtained from the polysomnographic study in the
whole population (n = 393 subjects).
Beta Beta 95% IC p value
AHI (log) Neck circumference (cm) 0.379 0.016 to 0.042 <0.001
Type 2 diabetes (yes/no) −0.223 −0.247 to −0.030 0.013
R2 = 0.217 Constant - −0.108 to 1.119 0.105
Apnea index (log) Gender (men/women) 0.357 0.276 to 0.823 <0.001
Type 2 diabetes (yes/no) −0.240 −0.708 to −0.106 0.009
R2 = 0.194 Constant - 0.694 to 1.826 <0.001
Hypopnea index (log) BMI (kg/m2) 0.271 0.003 to 0.021 0.007
R2 = 0.168 Constant - 0.309 to 0.980 <0.001
CT90 (log) Neck circumference (cm) 0.244 0.013 to 0.083 0.008
Type 2 diabetes (yes/no) −0.278 −0.718 to −0.160 0.002
Basal SaO2 (%) −0.227 −21.215 to −2.618 0.013
R2 = 0.221 Constant - 4.496 to 42.020 0.016
Average SaO2 (log) Basal SaO2 (%) 0.391 0.226 to 0.592 <0.001
Neck circumference (cm) −0.225 −0.002 to 0.000 0.012
R2 = 0.234 Constant - 0.826 to 1.562 <0.001
ODI-2% (log) Type 2 diabetes (yes/no) −0.280 −0.327 to −0.060 0.005
Neck circumference (cm) 0.278 0.007 to 0.040 0.005
R2 = 0.178 Constant - 0.044 to 1.527 0.038
ODI-3% (log) Neck circumference (cm) 0.314 0.013 to 0.048 0.001
Type 2 diabetes (yes/no) −0.235 −0.336 to −0.047 0.012
R2 = 0.175 Constant - −0.347 to 1.264 0.261
ODI-4% (log) Neck circumference (cm) 0.290 0.012 to 0.054 0.002
Type 2 diabetes (yes/no) −0.249 −0.400 to −0.062 0.008
R2 = 0.164 Constant - −0.618 to 1.267 0.496
ODI-5% (log) Neck circumference (cm) 0.306 0.015 to 0.062 0.001
Type 2 diabetes (yes/no) −0.236 −0.446 to −0.066 0.009
R2 = 0.169 Constant - −1.033 to 1.091 0.957
The independent variables included in all analyses were: gender, age, BMI, basal SaO2 (log), neck circumference, waist circumference, somnolence
score, and the presence or absence of T2D. AHI: apnea-hypopnea index; Beta: Standardized partial regression coefﬁcient. ODI: oxygen desaturation
index; BMI: body mass index.
doi:10.1371/journal.pone.0119073.t004
Sleep Breathing Pattern in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0119073 March 11, 2015 7 / 9
than did those subjects without diabetes. No differences in the number of central episodes be-
tween subjects with and without T2D were observed in our study. However, our results raise
the central issue of whether the normalization of blood glucose levels in humans can signifi-
cantly improve the severity of sleep apnea.
Finally, autonomic neuropathy has been implicated in the relationship between T2D and
sleep apnea. In fact, T2D patients with dysautonomia were more likely to have not only central,
but also obstructive sleep apnea, than those without it [21]. Therefore, an impairment of the
upper airway reflexes, possibly due to alterations to the autonomic nervous fibers involved in
their regulation, could lead to an inability of individuals with diabetes to respond appropriately
to nocturnal airflow reduction episodes, leading to more severe intermittent hypoxic episodes.
However, clinical disautonomy was within the exclusion criteria in the present study.
There are some potential limitations that should be taken into account in evaluating the re-
sults of our study. One limiting factor is that we recruited a population of mainly obese patients
with T2D, and consequently, further studies including a wider spectrum with overweight and
lesser degrees of obesity are needed. Second, this was a cross-sectional study and, therefore, a
causal link between T2D and the severity of SAHS cannot be drawn. In this regard, research ad-
dressed to determining whether the normalization of blood glucose levels could improve SAHS
events or hypoxia is warranted. Third, diabetes treatment may influence different conditions
that may alter the sleep pattern, and therefore polysomnographic measurements. However, as
subjects with T2D were not recruited on the basis of their treatment, almost all of them were
under combined management with subcutaneous and oral agents. Consequenly, data about the
relationship between baseline therapy and sleep breathing measures are difficult to establish,
indicating that further studies to address this possibility are also needed. Finally, although we
were able to establish two large and well-balanced groups matched on the basis of the known
risk factors that could affect the prevalence and severity of sleep-disordered breathing, there
may still be residual confounding factors that may contribute to our findings, such as the prev-
alence of depression or data regarding the evolution of T2D. Therefore, it is possible that these
residual or unmeasured confounders affect some of the results observed in our study.
In conclusion, T2D patients present a different pattern of sleep breathing which is charac-
terized by higher rates of sleep apneas, thus leading to more severe nocturnal hypoxemia and
daily sleepiness. However, the number of episodes of hypopnea is very similar to that observed
in subjects without diabetes. Whether patients with T2D need to be considered as a vulnerable
group, with special attention being paid screening for SAHS, and whether glycemic optimiza-
tion could be useful in improving the sleep breathing disorders are questions which remain to
be elucidated.
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